Combination of CAR-DC Vaccine and ICIs in Malignant Tumors

NCT05631886 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Solid Tumor, Adult
Lymphoma
EphA2 Overexpression
TP53 R273H
TP53 R175H
TP53 R248Q
TP53 R249S

Interventions

BIOLOGICAL: TP53-EphA-2-CAR-DC
DRUG: Abraxane
DRUG: Cyclophosphamide
DRUG: anti-PD-1 antibody
DRUG: Anti-CTLA4 Monoclonal Antibody

Sponsor

Chinese PLA General Hospital

Collaborators

[object Object]